Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 13/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.65 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582489 | 0.87 | CYSLTR1 (0.61) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6090813 | 0.86 | CYSLTR1 (0.69) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6090484 | 0.85 | CYSLTR1 (0.73) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL5725146 | 0.83 | CYSLTR1 (0.67) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6582739 | 0.82 | CYSLTR1 (0.62) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10635560 | 0.81 | CYSLTR1 (0.71) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089814 | 0.81 | CYSLTR1 (0.65) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6087603 | 0.81 | CYSLTR1 (0.64) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7714863 | 0.80 | CYSLTR1 (0.66) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089253 | 0.79 | CYSLTR1 (0.59) | CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |